Profile
Top Tier Capital Partners is a venture capital firm headquartered in San Francisco, with additional offices in Boston and London. Having a history that dates back to their predecessor firm Paul Capital, Top Tier Capital Partners has accumulated over two decades of experience in the venture capital industry. The firm specializes in managing multiple families of funds with a focus on primary commitments, LP and direct secondaries, and direct investments. They emphasize collaboration with limited partners and venture capital managers, offering insightful, hands-on counsel to nurture the growth of high-potential technology companies.
The firm invests across the innovation ecosystem, specifically targeting venture capital firms worldwide. Their investment approach includes making primary commitments to venture funds, providing flexible liquidity solutions through secondaries, and direct investments in high-growth, innovative companies. Though specific check sizes are not disclosed, Top Tier Capital Partners generally operates within the stages suited to venture-backed growth and established technology ventures.
Top Tier Capital Partners has backed a number of successful companies globally through its strategic partnerships throughout the venture capital community. However, the site does not list specific portfolio companies, indicating a focus on building long-lasting relationships rather than headline-grabbing single investments.
Industry
Top Tier Capital Partners Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Top Tier Venture Velocity Fund 4
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
Medical Devices
Life Sciences
|
Seed
Series A
Series B
|
North America
|
$5-10 m
|
$925 M
|
August 2022
|
|
European Investment Fund
|
Fund of funds
|
Biotechnology
Healthcare Services
Medical Devices
Life Sciences
|
Pre-seed
Seed
Series A
|
North America
|
$5-10 m
|
$283 M
|
May 2021
|
|
Top Tier Capital Partners European Venture Capital Fund of Funds
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
Medical Devices
Life Sciences
HealthTech
|
Pre-seed
Seed
Series A
|
North America
|
$5-10 m
|
$310 M
|
May 2021
|
|
Top Tier Venture Capital IX-B
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
Medical Devices
Life Sciences
|
Seed
Series A
|
North America
|
$5-10 m
|
$150 M
|
November 2019
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.